BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34157136)

  • 1. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.
    Rutten MGS; Derks TGJ; Huijkman NCA; Bos T; Kloosterhuis NJ; van de Kolk KCWA; Wolters JC; Koster MH; Bongiovanni L; Thomas RE; de Bruin A; van de Sluis B; Oosterveer MH
    Hepatology; 2021 Nov; 74(5):2491-2507. PubMed ID: 34157136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
    Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
    Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
    Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
    Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
    Hoogerland JA; Peeks F; Hijmans BS; Wolters JC; Kooijman S; Bos T; Bleeker A; van Dijk TH; Wolters H; Gerding A; van Eunen K; Havinga R; Pronk ACM; Rensen PCN; Mithieux G; Rajas F; Kuipers F; Reijngoud DJ; Derks TGJ; Oosterveer MH
    J Inherit Metab Dis; 2021 Jul; 44(4):879-892. PubMed ID: 33739445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
    La Rose AM; Bazioti V; Hoogerland JA; Svendsen AF; Groenen AG; van Faassen M; Rutten MGS; Kloosterhuis NJ; Dethmers-Ausema B; Nijland JH; Mithieux G; Rajas F; Kuipers F; Lukens MV; Soehnlein O; Oosterveer MH; Westerterp M
    Mol Metab; 2021 Nov; 53():101265. PubMed ID: 34091064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
    Saeed A; Hoogerland JA; Wessel H; Heegsma J; Derks TGJ; van der Veer E; Mithieux G; Rajas F; Oosterveer MH; Faber KN
    Hum Mol Genet; 2020 Jan; 29(2):264-273. PubMed ID: 31813960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.
    Clar J; Mutel E; Gri B; Creneguy A; Stefanutti A; Gaillard S; Ferry N; Beuf O; Mithieux G; Nguyen TH; Rajas F
    Hum Mol Genet; 2015 Apr; 24(8):2287-96. PubMed ID: 25561689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
    Chou JY; Zingone A; Pan CJ
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.
    Mutel E; Abdul-Wahed A; Ramamonjisoa N; Stefanutti A; Houberdon I; Cavassila S; Pilleul F; Beuf O; Gautier-Stein A; Penhoat A; Mithieux G; Rajas F
    J Hepatol; 2011 Mar; 54(3):529-37. PubMed ID: 21109326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
    Hijmans BS; Boss A; van Dijk TH; Soty M; Wolters H; Mutel E; Groen AK; Derks TGJ; Mithieux G; Heerschap A; Reijngoud DJ; Rajas F; Oosterveer MH
    Hepatology; 2017 Dec; 66(6):2042-2054. PubMed ID: 28727166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia.
    Rutten MGS; Lei Y; Hoogerland JH; Bloks VW; Yang H; Bos T; Krishnamurthy KA; Bleeker A; Koster MH; Thomas RE; Wolters JC; van den Bos H; Mithieux G; Rajas F; Mardinoglu A; Spierings DCJ; de Bruin A; van de Sluis B; Oosterveer MH
    Cancer Metab; 2023 Apr; 11(1):5. PubMed ID: 37085901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-based double-strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type-Ia.
    Samanta A; George N; Arnaoutova I; Chen HD; Mansfield BC; Hart C; Carlo T; Chou JY
    J Inherit Metab Dis; 2023 Nov; 46(6):1147-1158. PubMed ID: 37467014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
    Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
    Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
    Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
    Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
    Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of glycogen storage disease type 1a in a mouse model by gene therapy.
    Zingone A; Hiraiwa H; Pan CJ; Lin B; Chen H; Ward JM; Chou JY
    J Biol Chem; 2000 Jan; 275(2):828-32. PubMed ID: 10625614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.